Effect of monoclonal antibody drug therapy on mucosal biomarkers in airway disease: A systematic review

doi:10.1111/cea.13721

. 2020 Nov;50(11):1212-1222.

doi: 10.1111/cea.13721. Epub 2020 Sep 9.

Effect of monoclonal antibody drug therapy on mucosal biomarkers in airway disease: A systematic review

Sophie Walter¹, Jacqueline Ho¹, Raquel Alvarado¹, Janet Rimmer^{1

2

3}, Raewyn Campbell^{1

4

5}, Larry Kalish^{1

6}, Raymond Sacks^{1

5

6}, Richard J Harvey^{1

5}

Affiliations

¹ Rhinology and Skull Base Research Group, St Vincent's Centre for Applied Medical Research, University of New South Wales, Sydney, New South Wales, Australia.
² Woolcock Institute, University of Sydney, Sydney, New South Wales, Australia.
³ Faculty of Medicine, Notre Dame University, Sydney, New South Wales, Australia.
⁴ Department of Otolaryngology Head and Neck Surgery, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
⁵ Faculty of Medicine and Health Sciences, Macquarie University, Sydney, New South Wales, Australia.
⁶ Department of Otolaryngology, Head and Neck Surgery, Concord General Hospital, University of Sydney, Sydney, New South Wales, Australia.

PMID: 32808380
DOI: 10.1111/cea.13721

Effect of monoclonal antibody drug therapy on mucosal biomarkers in airway disease: A systematic review

Sophie Walter et al. Clin Exp Allergy. 2020 Nov.

. 2020 Nov;50(11):1212-1222.

doi: 10.1111/cea.13721. Epub 2020 Sep 9.

Authors

Sophie Walter¹, Jacqueline Ho¹, Raquel Alvarado¹, Janet Rimmer^{1

2

3}, Raewyn Campbell^{1

4

5}, Larry Kalish^{1

6}, Raymond Sacks^{1

5

6}, Richard J Harvey^{1

5}

Affiliations

¹ Rhinology and Skull Base Research Group, St Vincent's Centre for Applied Medical Research, University of New South Wales, Sydney, New South Wales, Australia.
² Woolcock Institute, University of Sydney, Sydney, New South Wales, Australia.
³ Faculty of Medicine, Notre Dame University, Sydney, New South Wales, Australia.
⁴ Department of Otolaryngology Head and Neck Surgery, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
⁵ Faculty of Medicine and Health Sciences, Macquarie University, Sydney, New South Wales, Australia.
⁶ Department of Otolaryngology, Head and Neck Surgery, Concord General Hospital, University of Sydney, Sydney, New South Wales, Australia.

PMID: 32808380
DOI: 10.1111/cea.13721

Abstract

Background: Monoclonal antibody therapies have a growing role in treating refractory airway disease.

Objective: The review aimed to summarize the response of respiratory mucosa to monoclonal antibody treatments in inflammatory airway conditions.

Design: We conducted a systematic review including risk of bias assessment.

Data sources: MEDLINE, EMBASE and PubMed from 1 January 2000 to 16 November 2019 were searched.

Eligibility criteria: Eligible studies assessed the immunological and histological response of airway mucosa to monoclonal antibody therapy compared with baseline or a comparison group in patients with respiratory diseases (asthma, chronic rhinosinusitis and allergic rhinitis). Any prospective interventional studies, including randomized controlled trials (RCTs) and single-arm trials, were eligible.

Results: There were 4195 articles screened, and full-text analysis produced n = 11 studies with extractable data. Nine were RCTs, and two were single-arm trials. These studies focused on asthma (n = 9 articles), chronic rhinosinusitis (n = 1) and allergic rhinitis (n = 1). Five monoclonal antibody drugs were assessed (omalizumab, mepolizumab, dupilumab, benralizumab and tralokinumab). Risk of bias was low (n = 6) or unclear (n = 3) in the RCTs and moderate in the single-arm trials. Omalizumab reduced the mucosal concentration of its target, IgE. Dupilumab reduced the concentration of one of its targets, IL-13, but not IL-4. Omalizumab, mepolizumab and benralizumab reduced tissue eosinophil cell density. Dupilumab decreased mucosal eosinophil granule proteins. Tralokinumab did not affect airway mucosa.

Conclusions: Knowledge of the expected biological response of monoclonal antibody therapy on biomarkers in disease tissue provides an important supplement to data about clinical outcomes. An understanding of the biological effect is essential to identify likely responders, reasons for treatment failure and necessary adjustments to monoclonal antibody treatment. Further investigation into the effect of monoclonal antibody therapy on disease mucosa and more precise endotyping are required to move closer to achieving personalized medicine.

Keywords: ENT; asthma; biomarker; monoclonal antibody; mucosa; rhinitis.

PubMed Disclaimer

Cited by

Biologics for chronic rhinosinusitis.
Chong LY, Piromchai P, Sharp S, Snidvongs K, Webster KE, Philpott C, Hopkins C, Burton MJ. Chong LY, et al. Cochrane Database Syst Rev. 2021 Mar 12;3(3):CD013513. doi: 10.1002/14651858.CD013513.pub3. Cochrane Database Syst Rev. 2021. PMID: 33710614 Free PMC article.
Omalizumab: An Optimal Choice for Patients with Severe Allergic Asthma.
Kotoulas SC, Tsiouprou I, Fouka E, Pataka A, Papakosta D, Porpodis K. Kotoulas SC, et al. J Pers Med. 2022 Jan 26;12(2):165. doi: 10.3390/jpm12020165. J Pers Med. 2022. PMID: 35207654 Free PMC article. Review.

References

REFERENCES

1. Barnes PJ. The cytokine network in asthma and chronic obstructive pulmonary disease. J Clin Invest. 2008;118(11):3546-3556.
1. Fokkens WJ, Lund VJ, Hopkins C, et al. European position paper on rhinosinusitis and nasal polyps 2020. Rhinology. 2020;58(29):1-464.
1. Kaur R, Chupp G. Phenotypes and endotypes of adult asthma: Moving toward precision medicine. J Allergy Clin Immunol. 2019;144(1):1-12.
1. Jutel M, Gajdanowicz P. Revised disease nomenclature including disease endotypes. In: Agache I, Hellings P, eds. Implementing Precision Medicine in Best Practices of Chronic Airway Diseases. London, UK: Academic Press; 2019:27-29.
1. Feng CH, Miller MD, Simon RA. The united allergic airway: connections between allergic rhinitis, asthma, and chronic sinusitis. Am J Rhinol Allergy. 2012;26(3):187-190.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wiley
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal

[1] Barnes PJ. The cytokine network in asthma and chronic obstructive pulmonary disease. J Clin Invest. 2008;118(11):3546-3556.

[2] Barnes PJ. The cytokine network in asthma and chronic obstructive pulmonary disease. J Clin Invest. 2008;118(11):3546-3556.

[3] Fokkens WJ, Lund VJ, Hopkins C, et al. European position paper on rhinosinusitis and nasal polyps 2020. Rhinology. 2020;58(29):1-464.

[4] Fokkens WJ, Lund VJ, Hopkins C, et al. European position paper on rhinosinusitis and nasal polyps 2020. Rhinology. 2020;58(29):1-464.

[5] Kaur R, Chupp G. Phenotypes and endotypes of adult asthma: Moving toward precision medicine. J Allergy Clin Immunol. 2019;144(1):1-12.

[6] Kaur R, Chupp G. Phenotypes and endotypes of adult asthma: Moving toward precision medicine. J Allergy Clin Immunol. 2019;144(1):1-12.

[7] Jutel M, Gajdanowicz P. Revised disease nomenclature including disease endotypes. In: Agache I, Hellings P, eds. Implementing Precision Medicine in Best Practices of Chronic Airway Diseases. London, UK: Academic Press; 2019:27-29.

[8] Jutel M, Gajdanowicz P. Revised disease nomenclature including disease endotypes. In: Agache I, Hellings P, eds. Implementing Precision Medicine in Best Practices of Chronic Airway Diseases. London, UK: Academic Press; 2019:27-29.

[9] Feng CH, Miller MD, Simon RA. The united allergic airway: connections between allergic rhinitis, asthma, and chronic sinusitis. Am J Rhinol Allergy. 2012;26(3):187-190.

[10] Feng CH, Miller MD, Simon RA. The united allergic airway: connections between allergic rhinitis, asthma, and chronic sinusitis. Am J Rhinol Allergy. 2012;26(3):187-190.

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Effect of monoclonal antibody drug therapy on mucosal biomarkers in airway disease: A systematic review

Affiliations

Effect of monoclonal antibody drug therapy on mucosal biomarkers in airway disease: A systematic review

Authors

Affiliations

Abstract

Similar articles

Cited by

References

REFERENCES

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Research Materials

Miscellaneous

Abstract

Similar articles

Cited by

References

REFERENCES

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Research Materials

Miscellaneous